



+++ VERTEX (VRTX): Positive results of a phase Ib clinical trial of **VX-950**, an oral **hepatitis C virus protease inhibitor**.

+++ GERON (GERN): Published studies demonstrate that hematopoietic stem cells derived from **human embryonic stem cells** can establish hematopoiesis in mouse models, leading to production of all major human blood cell types.

+++ XOMA (XOMA): Posted a first-quarter profit of \$30.1 million or 28 cents a share. Results for the quarter include a \$40.9 million gain. Revenues were \$3 million vs. \$170,000 a year earlier. Firm has over \$60 million in cash. Important is that there were **contract revenues** of \$1.3 million for the three months ended March 31, 2005, **compared with zero** for the three months ended March 31, 2004. The revenues came from clinical trial services performed on behalf of Genentech, Inc. ("Genentech") and contract manufacturing services performed under the National Institute of Allergy and Infectious Diseases to develop three anti-botulinum neurotoxin monoclonal antibody therapeutics.

+++ ARRAY (ARRY): While developing far-reaching drugs through very advanced technology, Array attracted alliances and as able to generate near-term revenues that reached \$11.6 million in a quarter compared to \$9.7 million for the same period in fiscal 2004. Net loss was \$6.2 million, or (\$0.16) per share, for the third quarter, compared to a net loss of \$9.7 million, for the same quarter in fiscal 2004. **In nine months, the firm was able to generate over \$30 million in revenues, without putting one product yet on the market.**

PROHOST NEWSLETTER WILL BE POSTED TODAY

PROHOST RESEARCH
P.O.BOX 640 429
Oakland Gardens, Ny 11364
Telephone : 516 678 1335
Fax 718 423 2731
E-mail prohost@aol.com

Prohost is independent publication providing information on biotech companies. Prohost does not accept compensation from companies that are featured or profiled. It is strongly recommended that any purchase or sale decisions to any of the featured companies be discussed with a financial advisor or broker prior to completing any such purchase or sale decision. All statements or expressions are the opinion of Prohost and are not meant to be a solicitation or recommendation to buy, sell, or hold securities. Investing in embryonic companies, micro-cap and growth securities is highly speculative and carries a high degree of risk. It is possible that an investor can lose all of his/her investment in this type of companies that are profiled. The information that Prohost relies on is either through the profiled company, news services, research reports, interviews, or other outside sources that Prohost believes are reliable. Prohost makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure of the profiled companies and accepts no responsibilities for inaccuracies or misleading content in any material supplied by those clients. There can be no assurance that future events relating to the profiled company will occur as anticipated. The information contained herein is provided as an information service only. Past performance of featured companies does not guarantee the future success of any currently featured or profiled company. We encourage our readers to invest carefully and read the investor information provided by the Securities and Exchange Commission ("SEC") and/or the National Association of Securities Dealers ("NASD"). We also strongly recommend that you read the SEC advisory to investors concerning Internet Stock Fraud, which can be found at: <http://www.sec.gov/consumer/cyberfr.htm>